Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL
Status:
Recruiting
Trial end date:
2023-07-30
Target enrollment:
Participant gender:
Summary
This study was a prospective, multi-center, single-arm, Phase II clinical study. Compared
with the literature data, objective response rate (ORR) and complete response rate (CR) were
the primary endpoint, and 1-year and 2-year progression-free survival (PFS) and 2-year
overall survival (OS) were the secondary endpoint. To evaluate the efficacy and safety of
TR2-ICE sequential Tirelarizin, lenalidomide alone, or both maintenance therapy in the rescue
of patients with relapsed and refractory diffuse large B or high-grade B-cell lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Affiliated Hospital to Academy of Military Medical Sciences
Collaborators:
Beijing Cancer Hospital Cancer Institute and Hospital, Chinese Academy of Medical Sciences